Savara Inc. (NASDAQ:SVRA) disclosed in an 8-K filing to the Securities and Exchange Commission on January 23, 2025, that the company’s Board of Directors has approved the target bonus amounts for its executive officers for the year ended December 31, 2025.
The approved target bonus amounts for Savara’s executive officers for the year ended December 31, 2025 are as follows:
– Raymond Pratt, Chief Medical Officer: Target Bonus of $200,400, representing 40% of base salary.
– Dave Lowrance, Chief Financial & Administrative Officer: Target Bonus of $188,400, representing 40% of base salary.
– Rob Lutz, Chief Operating Officer: Target Bonus of $188,400, representing 40% of base salary.
– Anne Erickson, Chief Business Officer: Target Bonus of $165,080, representing 40% of base salary.
– Braden Parker, Chief Commercial Officer: Target Bonus of $180,000, representing 40% of base salary.
It is important to note that actual bonus amounts paid to the executive officers may vary from the target bonus amounts. The total bonus payments will be dependent on the achievement of specific performance goals. The Board retains the discretion to award bonus amounts that differ based on the attainment of performance goals above or below expectations.
For Mr. Pauls, the achievement of corporate performance measures will account for 100% of his target bonus award. For each of Dr. Pratt, Mr. Lowrance, Mr. Lutz, Ms. Erickson, and Mr. Parker, 75% of the target bonus award will be based on corporate performance measures, and individual performance measures will represent the remaining 25% of the target bonus award.
The 8-K filing further included that the report was signed on behalf of Savara Inc. by Dave Lowrance, the Chief Financial & Administrative Officer.
This disclosure provides clarity regarding the target bonus amounts set for Savara’s executive team for the fiscal year 2025, aligned with the company’s performance goals and strategies.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Savara’s 8K filing here.
About Savara
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also
- Five stocks we like better than Savara
- The Most Important Warren Buffett Stock for Investors: His Own
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- The 3 Best Retail Stocks to Shop for in August
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- What is the S&P 500 and How It is Distinct from Other Indexes
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
